Business Wire

The Estée Lauder Companies Launches 2023 Breast Cancer Campaign: Beautifully United to Help End Breast Cancer

Share

For more than 30 years, The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) has been dedicated to advancing the possibility of a breast cancer-free world for all. This October, The Estée Lauder Companies (ELC) honors Breast Cancer Awareness Month by launching The Campaign in support of the global breast cancer community.

As ELC’s largest corporate social impact program, The Campaign continues to inspire purpose-driven action and is a cornerstone of the company’s social investments in women’s advancement, health and education. Through The Campaign, ELC has also been a longstanding supporter of women in science, research and medicine – funding numerous grants and programs around the world and accelerating opportunities for women in STEM.

The Campaign was founded by Evelyn H. Lauder in 1992 with the launch of the iconic Pink Ribbon. At a time when breast cancer wasn’t spoken about openly, Evelyn and ELC saw an opportunity to bring awareness to the disease and address stigmas in women’s health – inspiring a global movement around The Campaign’s mission to help create a breast cancer-free world for all.

Together, The Estée Lauder Companies’ Breast Cancer Campaign and The Estée Lauder Companies Charitable Foundation (ELCCF) have funded more than $118 million globally for life saving research, education, and medical services, with more than $93 million funding medical research through the Breast Cancer Research Foundation (BCRF). BCRF, also founded by Evelyn Lauder in 1993, is The Campaign’s leading non-profit partner, dedicated to advancing the world’s most promising research to eradicate breast cancer.

In honor of The Campaign’s 30th Anniversary in 2022, ELCCF made a commitment to donate $15 million over five years to BCRF to fund groundbreaking research that will further the goal of reducing breast cancer disparities and improving outcomes. This comprehensive study of the intersection of social determinants of health, comorbidities and the biology of breast cancer in Black women has the potential to significantly impact breast cancer disparities globally. A diverse steering committee, as well as sub-committees, comprised of BCRF experts in disparities from acclaimed academic and medical institutions from across the country have established initial targets critical to identifying the roots of health equity and disparities in breast cancer outcomes. Information from thousands of patients will build this vital data-generating project and is the first step in this multi-year initiative.

This year, The Campaign will:

  • Support 60+ organizations worldwide aligned to the diverse needs of local communities
  • Honor the 20th Anniversary of The Breast Cancer Campaign in China, including the illumination of No.1 Wai Tan Yuan, Shanghai
  • Address disparities that exist across the entire breast cancer landscape
  • Fund medical research and fellowships worldwide
  • Fund medical resources and services including access to mammograms/screenings for vulnerable groups with limited access to healthcare
  • Provide support, therapy and counseling programs
  • Host and convene events to advance education on breast health with key opinion leaders and experts - encouraging stakeholders everywhere to become breast health advocates
  • Issue an Instagram call-to-action (@esteelaudercompanies) on October 1 to engage audiences and raise funds for BCRF using #TimeToEndBreastCancer
  • Engage ELC’s brands: AERIN Beauty, Aveda, Bobbi Brown Cosmetics, Bumble and bumble, Clinique, Darphin, Dr.Jart+, Editions de Parfums Frédéric Malle, Estée Lauder, Jo Malone London, KILIAN PARIS, La Mer, Lab Series, Origins, Smashbox, TOM FORD BEAUTY and Too Faced – with each donating to BCRF and/or local cancer-focused organizations around the world through product sales or flat donations (brand participation varying by market)
  • Illuminate buildings, monuments and landmarks around the world in pink to raise awareness, including Empire State Building, New York City; Eiffel Tower, Paris; Burj Al Arab, United Arab Emirates, among others

"ELC has an unwavering commitment to social impact, with The Breast Cancer Campaign at the forefront of these efforts. I am incredibly proud of the progress we have made ever since my mother, Evelyn Lauder, started The Campaign more than 30 years ago," said William P. Lauder, Executive Chairman, The Estée Lauder Companies Inc. "Our passionate employees, consumers and partners have united to advance possibilities for those affected by this disease. Together, we will continue powering progress, until we realize my mother’s vision of a breast cancer-free world for all."

The call to end breast cancer is more urgent than ever as breast cancer is the most commonly diagnosed cancer worldwide. As long as breast cancer is a life-threatening disease, ELC’s commitment remains unwavering.

To learn more, visit: ELCompanies.com/BreastCancerCampaign and @esteelaudercompanies on Instagram.

About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

ELC-C

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Erin Cohen
The Estée Lauder Companies
ercohen@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye